Use of anticholinergics and the risk of cognitive impairment in an African American population

N. L. Campbell, Malaz Boustani, K. A. Lane, Sujuan Gao, Hugh Hendrie, Babar Khan, J. R. Murrell, Frederick Unverzagt, Ann Hake, V. Smith-Gamble, Kathleen Hall

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who were enrolled in the Indianapolis-Ibadan Dementia Project between 2001 and 2007 and who had normal cognitive function at baseline. The exposure group included those who reported the baseline use of possible or definite anticholinergics as determined by the Anticholinergic Cognitive Burden scale. Our main outcome measure was the incidence of cognitive impairment, defined as either dementia or cognitive impairment not dementia, or poor performance on a dementia screening instrument during the follow-up period. Results: At baseline, 53% of the population used a possible anticholinergic, and 11% used a definite anticholinergic. After adjusting for age, gender, educational level, and baseline cognitive performance, the number of definite anticholinergics was associated with an increased risk of cognitive impairment (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.07-1.99; p = 0.02), whereas the number of possible anticholinergics at baseline did not increase the risk (OR 0.96, 95% CI 0.85-1.09; p = 0.55). The risk of cognitive impairment among definite anticholinergic users was increased if they were not carriers of the APOE ε4 allele (OR 1.77, 95% CI 1.03-3.05; p = 0.04). Conclusions: Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans.

Original languageEnglish
Pages (from-to)152-159
Number of pages8
JournalNeurology
Volume75
Issue number2
DOIs
StatePublished - Jul 13 2010

Fingerprint

Cholinergic Antagonists
African Americans
Population
Dementia
Odds Ratio
Confidence Intervals
Incidence
Independent Living
Cognitive Dysfunction
Cognition
Observational Studies
Longitudinal Studies
Alleles
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Use of anticholinergics and the risk of cognitive impairment in an African American population. / Campbell, N. L.; Boustani, Malaz; Lane, K. A.; Gao, Sujuan; Hendrie, Hugh; Khan, Babar; Murrell, J. R.; Unverzagt, Frederick; Hake, Ann; Smith-Gamble, V.; Hall, Kathleen.

In: Neurology, Vol. 75, No. 2, 13.07.2010, p. 152-159.

Research output: Contribution to journalArticle

@article{cfc2e022c9da49bc8703c4fc9801ef7a,
title = "Use of anticholinergics and the risk of cognitive impairment in an African American population",
abstract = "Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who were enrolled in the Indianapolis-Ibadan Dementia Project between 2001 and 2007 and who had normal cognitive function at baseline. The exposure group included those who reported the baseline use of possible or definite anticholinergics as determined by the Anticholinergic Cognitive Burden scale. Our main outcome measure was the incidence of cognitive impairment, defined as either dementia or cognitive impairment not dementia, or poor performance on a dementia screening instrument during the follow-up period. Results: At baseline, 53{\%} of the population used a possible anticholinergic, and 11{\%} used a definite anticholinergic. After adjusting for age, gender, educational level, and baseline cognitive performance, the number of definite anticholinergics was associated with an increased risk of cognitive impairment (odds ratio [OR] 1.46, 95{\%} confidence interval [CI] 1.07-1.99; p = 0.02), whereas the number of possible anticholinergics at baseline did not increase the risk (OR 0.96, 95{\%} CI 0.85-1.09; p = 0.55). The risk of cognitive impairment among definite anticholinergic users was increased if they were not carriers of the APOE ε4 allele (OR 1.77, 95{\%} CI 1.03-3.05; p = 0.04). Conclusions: Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans.",
author = "Campbell, {N. L.} and Malaz Boustani and Lane, {K. A.} and Sujuan Gao and Hugh Hendrie and Babar Khan and Murrell, {J. R.} and Frederick Unverzagt and Ann Hake and V. Smith-Gamble and Kathleen Hall",
year = "2010",
month = "7",
day = "13",
doi = "10.1212/WNL.0b013e3181e7f2ab",
language = "English",
volume = "75",
pages = "152--159",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Use of anticholinergics and the risk of cognitive impairment in an African American population

AU - Campbell, N. L.

AU - Boustani, Malaz

AU - Lane, K. A.

AU - Gao, Sujuan

AU - Hendrie, Hugh

AU - Khan, Babar

AU - Murrell, J. R.

AU - Unverzagt, Frederick

AU - Hake, Ann

AU - Smith-Gamble, V.

AU - Hall, Kathleen

PY - 2010/7/13

Y1 - 2010/7/13

N2 - Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who were enrolled in the Indianapolis-Ibadan Dementia Project between 2001 and 2007 and who had normal cognitive function at baseline. The exposure group included those who reported the baseline use of possible or definite anticholinergics as determined by the Anticholinergic Cognitive Burden scale. Our main outcome measure was the incidence of cognitive impairment, defined as either dementia or cognitive impairment not dementia, or poor performance on a dementia screening instrument during the follow-up period. Results: At baseline, 53% of the population used a possible anticholinergic, and 11% used a definite anticholinergic. After adjusting for age, gender, educational level, and baseline cognitive performance, the number of definite anticholinergics was associated with an increased risk of cognitive impairment (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.07-1.99; p = 0.02), whereas the number of possible anticholinergics at baseline did not increase the risk (OR 0.96, 95% CI 0.85-1.09; p = 0.55). The risk of cognitive impairment among definite anticholinergic users was increased if they were not carriers of the APOE ε4 allele (OR 1.77, 95% CI 1.03-3.05; p = 0.04). Conclusions: Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans.

AB - Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment. Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who were enrolled in the Indianapolis-Ibadan Dementia Project between 2001 and 2007 and who had normal cognitive function at baseline. The exposure group included those who reported the baseline use of possible or definite anticholinergics as determined by the Anticholinergic Cognitive Burden scale. Our main outcome measure was the incidence of cognitive impairment, defined as either dementia or cognitive impairment not dementia, or poor performance on a dementia screening instrument during the follow-up period. Results: At baseline, 53% of the population used a possible anticholinergic, and 11% used a definite anticholinergic. After adjusting for age, gender, educational level, and baseline cognitive performance, the number of definite anticholinergics was associated with an increased risk of cognitive impairment (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.07-1.99; p = 0.02), whereas the number of possible anticholinergics at baseline did not increase the risk (OR 0.96, 95% CI 0.85-1.09; p = 0.55). The risk of cognitive impairment among definite anticholinergic users was increased if they were not carriers of the APOE ε4 allele (OR 1.77, 95% CI 1.03-3.05; p = 0.04). Conclusions: Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans.

UR - http://www.scopus.com/inward/record.url?scp=77954743487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954743487&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181e7f2ab

DO - 10.1212/WNL.0b013e3181e7f2ab

M3 - Article

C2 - 20625168

AN - SCOPUS:77954743487

VL - 75

SP - 152

EP - 159

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -